Why is Krishna Institu. falling/rising?

Recent Price Movement and Market Context

The stock has been under pressure for the last five consecutive trading days, losing 5.12% over this period, significantly underperforming the broader Sensex, which declined by only 0.84%. The intraday low of ₹661 marked a 2.39% drop from the previous close, signalling persistent selling pressure. Notably, Krishna Institute of Medical Sciences is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical setup.

Despite this short-term weakness, the stock has delivered robust returns over longer horizons. Year-to-date, it has gained 11.58%, outperforming the Sensex’s 8.00% rise. Over one year, the stock’s 9.09% return also surpasses the Sensex’s 3.53%, while its three-year performance is particularly impressive, with a gain of 131.10% compared to the benchmark’s 35.72%. This reflects the company’s consistent ability to generate shareholder value over time.

Fundamental Strengths Supporting the Stock

Krishna Institute of Medical Sciences boasts a high return on capital employed (ROCE) of 22.32%, reflecting efficient management and effective utilisation of capital. The company’s ability to service its debt is also strong, with an average EBIT to interest ratio of 12.76, indicating comfortable coverage of interest expenses. Institutional investors hold a significant 47.14% stake, suggesting confidence from knowledgeable market participants who typically conduct thorough fundamental analysis.

Moreover, the company has consistently outperformed the BSE500 index over the past three years, reinforcing its track record of delivering steady returns. These factors collectively underpin the stock’s appeal to long-term investors despite recent volatility.

Challenges Weighing on the Stock Price

However, the recent price decline is largely attributable to disappointing financial results and concerns over growth sustainability. The company’s operating profit growth has been modest, expanding at an annual rate of just 9.36% over the last five years, which may be viewed as underwhelming by growth-focused investors.

More critically, the latest quarterly and half-yearly results reveal troubling trends. Interest expenses have surged by 48.09% to ₹77.60 crores in the latest six months, exerting pressure on profitability. Profit before tax excluding other income (PBT less OI) fell sharply by 25.6% compared to the previous four-quarter average, signalling operational challenges. Net profit after tax (PAT) also declined by 25.00% over the same period, further dampening investor sentiment.

Valuation metrics add to the cautious outlook. The stock’s ROCE of 10.6 and an enterprise value to capital employed ratio of 5.6 suggest a relatively expensive valuation, even though it trades at a discount to its peers’ historical averages. Additionally, while the stock has generated a 9.09% return over the past year, its profits have contracted by 1.2%, raising questions about the quality of earnings growth.

Investor Participation and Liquidity

Interestingly, investor participation has increased recently, with delivery volumes on 9 Dec rising by 132.79% to 4.07 lakh shares compared to the five-day average. This heightened activity suggests that while some investors are exiting, others may be repositioning, possibly anticipating a turnaround or bargain hunting at lower price levels. The stock remains sufficiently liquid, supporting trade sizes of approximately ₹0.53 crore based on 2% of the five-day average traded value.

Conclusion

In summary, Krishna Institute of Medical Sciences Ltd’s recent share price decline is primarily driven by disappointing recent earnings, rising interest costs, and a lack of robust long-term profit growth. Despite strong management efficiency, solid institutional backing, and impressive historical returns, the stock faces near-term headwinds that have led to a five-day losing streak and technical weakness below key moving averages. Investors should weigh these challenges against the company’s fundamental strengths and consider valuation carefully before making investment decisions.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →